# reload+after+2024-01-23 16:46:59.550151
address1§399 Binney Street
address2§2nd Floor
city§Cambridge
state§MA
zip§02139
country§United States
phone§617 370 8837
website§https://www.relaytx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and GDC-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
fullTimeEmployees§343
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Alexis A. Borisy A.M.', 'age': 51, 'title': 'Co-Founder & Independent Chairman', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 85000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS', 'age': 49, 'title': 'CEO, President & Director', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 1026746, 'exercisedValue': 4483852, 'unexercisedValue': 9815068}, {'maxAge': 1, 'name': 'Dr. Mark  Murcko Ph.D.', 'age': 63, 'title': 'Co-Founder & Director', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 50000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas  Catinazzo', 'age': 46, 'title': 'Chief Financial Officer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 599825, 'exercisedValue': 1023379, 'unexercisedValue': 815077}, {'maxAge': 1, 'name': 'Mr. Brian R. Adams J.D.', 'age': 49, 'title': 'Chief Legal Officer & Secretary', 'yearBorn': 1974, 'fiscalYear': 2022, 'totalPay': 598534, 'exercisedValue': 0, 'unexercisedValue': 2299209}, {'maxAge': 1, 'name': 'Dr. Donald A. Bergstrom M.D., Ph.D.', 'age': 51, 'title': 'President of Research & Development', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 711255, 'exercisedValue': 3393188, 'unexercisedValue': 2519389}, {'maxAge': 1, 'name': 'Mr. Peter  Rahmer', 'title': 'Chief Corporate Development Officer', 'fiscalYear': 2022, 'totalPay': 570517, 'exercisedValue': 519960, 'unexercisedValue': 153865}, {'maxAge': 1, 'name': 'Dr. Deborah  Palestrant Ph.D.', 'title': 'Vice President of Corporate Development & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Jim  Watters Ph.D.', 'title': 'Chief Scientific Officer of Late Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Beni B. Wolf M.D., Ph.D.', 'title': 'Chief Medical Officer & Head of Precision Medicine', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§6
compensationRisk§8
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.659
priceToSalesTrailing12Months§54.945484
currency§USD
dateShortInterest§1702598400
forwardEps§-3.09
pegRatio§0.04
exchange§NGM
quoteType§EQUITY
shortName§Relay Therapeutics, Inc.
longName§Relay Therapeutics, Inc.
firstTradeDateEpochUtc§1594906200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b35ff0f0-789e-3476-a6a9-2f56995bbd89
gmtOffSetMilliseconds§-18000000
targetHighPrice§33.0
targetLowPrice§9.4
targetMeanPrice§22.4
targetMedianPrice§24.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§11
quickRatio§15.977
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
